NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 739-742

  Kanold, Justyna ^a,b,c   Paillard, Catherine ^a,b   Tchirkov, Andrei ^a,c   Lang, Peter ^d   Kelly, Antony ^e   Halle, Pascale ^a,b   Isfan, Florentina ^a,b,c   Merlin, Etienne ^a,b   Marabelle, Aurelien ^f   Rochette, Emmanuelle ^a,b   Deméocq, François ^a,b,c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e CENTRE JEAN PERRIN   (France)

^f CENTRE LÉON BÉRARD   (France)

Author keywords

Graft versus tumour effect; HSCT; Neuroblastoma; NK cells

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 2; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHILD; DRUG MEGADOSE; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW NEOPLASMS; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM, RESIDUAL; NEUROBLASTOMA; NEUROPEPTIDES; REMISSION INDUCTION; TOPOTECAN; TRANSCRIPTION FACTORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE;

EID: 84864923799     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24030     Document Type: Article

References (13)

1. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007-1013.
2. Ladenstein R, Potschger U, Hartman O, et al. On behalf of the EBMT Paediatric Working Party 28 years of high-dose therapy and SCT for neuroblastoma in Europe: Lessons from more than 4000 procedures Bone Marrow Transplant 2008; 41: 118-127.
3. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res 2003; 12: 435-442.
4. Viprey VF, Lastowska MA, Corrias MV, et al. Minimal disease monitoring by QRT-PCR: Guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 2008; 216: 245-252.
5. Lang P, Pfeiffer M, Müller I, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: Preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006; 218: 321-326.
6. Baldomero H, Gratwohl M, Gratwohl A, et al., European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: Trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485-501.
7. Ljungman P, Bregni M, Brune M, et al. European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
8. Inoue M, Nakano T, Yoneda A, et al. Graft versus-tumor effect in a patient with advanced neuroblastoma who received HLA haploidentical bone marrow transplantation. Bone Marrow Transplant 2003; 32: 103-106.
9. Perez-Martinez A, Leung W, Munoz E, et al. KIR-HLA receptor-ligand mismatch associated with a graft versus tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumor. Pediatr Blood Cancer 2009; 12: 1-5.
10. Toporski J, Garkavij M, Tennvall J, et al. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant 2009; 15: 1077-1085.
11. Sung KW, Park JE, Chueh HW, et al. Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer 2011; 57: 660-665.
12. Ménard C, Martin F, Apetoh L, et al. Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579-1587.
13. Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens antitumor activity, toxicity, and immunomodulatory effects. Cancer 2010; 116: 2868-2877.